Categories AlphaGraphs, Earnings, Health Care
A visual dashboard of AbbVie’s Q1 2020 earnings results
AbbVie (NYSE: ABBV) reported its first quarter 2020 earnings results, which surpassed the market’s views. Adjusted EPS of $2.42 and revenue of $8.62 billion, topped analysts’ EPS target of $2.25 and revenue target of $8.33 billion. For fiscal 2020, the drug manufacturer lifted its 2020 GAAP EPS outlook, while reaffirmed the non-GAAP EPS target. ABBV stock rose about 1% in the pre-market session.
AbbVie lifted its standalone GAAP EPS guidance for the full-year 2020 to $7.66 to $7.76 from an earlier range of $7.60 to $7.70, representing growth of 44.9% at the midpoint and confirmed the previous expectation of standalone adjusted diluted EPS of $9.61 to $9.71, representing growth of 8.1% at the midpoint.
[irp posts=”51574″]
AbbVie has initiated the Phase 2 iNSPIRE clinical trial to evaluate the potential of IMBRUVICA drug to treat patients with moderate to severe COVID-19. AbbVie is also supporting COVID-19 clinical research by collaborating with health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of KALETRA/ALUVIA, the company’s antiretroviral therapy for the treatment of HIV, against COVID-19.
After reaching a 52-week high ($97.86) February 12, ABBV stock fell to its yearly low ($62.55) on March 23. ABBV shares have retreated 7% since the beginning of this year.
Most Popular
Citigroup set to report Q4 2025 earnings. Here’s what to expect
Citigroup Inc. (NYSE: C) has undergone a sweeping transformation in recent years, emerging as a more streamlined and profitable financial institution. The bank's performance in recent quarters has underscored the
Home Depot (HD), Lowe’s (LOW): Home improvement pressures not expected to abate soon
Home improvement retailers Home Depot (NYSE: HD) and Lowe’s Companies, Inc. (NYSE: LOW) have been facing a challenging operating environment for a while now. The companies have been battling macroeconomic
Earnings Summary: AngioDynamics (ANGO) Q2 FY26 sales increase 8.8%
Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Tuesday reported an increase in net sales for the second quarter of fiscal 2026. In Q2, net sales increased 8.8% year-over-year to
Comments